Cue Biopharma (NASDAQ:CUE) Releases Earnings Results

Cue Biopharma (NASDAQ:CUE) released its quarterly earnings data on Monday. The company reported $0.01 earnings per share (EPS) for the quarter, FiscalAI reports. Cue Biopharma had a negative net margin of 96.85% and a negative return on equity of 210.10%. The firm had revenue of $21.94 million during the quarter.

Cue Biopharma Stock Performance

NASDAQ CUE opened at $0.27 on Wednesday. The stock has a fifty day simple moving average of $0.32 and a 200-day simple moving average of $0.52. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.01. The stock has a market cap of $21.38 million, a PE ratio of -0.85 and a beta of 1.52. Cue Biopharma has a twelve month low of $0.23 and a twelve month high of $1.05.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. increased its position in shares of Cue Biopharma by 730.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after acquiring an additional 73,000 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Cue Biopharma in the 3rd quarter worth approximately $62,000. Stifel Financial Corp boosted its position in shares of Cue Biopharma by 25.4% during the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after purchasing an additional 50,000 shares during the period. Texas Capital Bank Wealth Management Services Inc boosted its position in shares of Cue Biopharma by 1,231.2% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after purchasing an additional 407,568 shares during the period. Finally, Boothbay Fund Management LLC increased its holdings in Cue Biopharma by 15.3% in the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock valued at $215,000 after purchasing an additional 93,333 shares during the last quarter. Hedge funds and other institutional investors own 35.04% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cue Biopharma in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Cue Biopharma presently has a consensus rating of “Sell”.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.